Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H21F3O5S |
| Molecular Weight | 430.4398 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc2C[C@]([H])(Cc2c(c1)Oc3cccc(c3)OS(=O)(=O)CCCC(F)(F)F)CO
InChI
InChIKey=XJURALZPEJKKOV-CQSZACIVSA-N
InChI=1S/C20H21F3O5S/c21-20(22,23)8-3-9-29(25,26)28-17-6-2-5-16(12-17)27-19-7-1-4-15-10-14(13-24)11-18(15)19/h1-2,4-7,12,14,24H,3,8-11,13H2/t14-/m1/s1
| Molecular Formula | C20H21F3O5S |
| Molecular Weight | 430.4398 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 00:09:12 UTC 2021
by
admin
on
Sat Jun 26 00:09:12 UTC 2021
|
| Record UNII |
SRX4T6TMUS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/08/560
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9845561
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
PRIMARY | |||
|
SRX4T6TMUS
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
PRIMARY | |||
|
BAY 38-7271
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
PRIMARY | Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has now been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials. But its development appears stopped. | ||
|
212188-60-8
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
PRIMARY | |||
|
BAY-38-7271
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
PRIMARY | BAY 38-7271 (KN 38-7271) CAS: 212188-60-8 | ||
|
SUB195628
Created by
admin on Sat Jun 26 00:09:12 UTC 2021 , Edited by admin on Sat Jun 26 00:09:12 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
